CTLA-4 Blockade Resistance after Relatlimab and Nivolumab

Ipilimumab after Anti-PD-1 and Anti-LAG-3 Therapy Data were pooled from 36 patients who received the anti-CTLA-4 antibody ipilimumab after metastatic melanoma progression during therapy with nivolumab (anti-PD-1) plus relatlimab (anti-LAG-3) to assess whether immunotherapies that target distinct checkpoints have different mechanisms of action. The findings suggest that cross-resistance emerges when tumors progress with immune checkpoint inhibitors.

Automated summary

The study suggests that tumors that become resistant to PD-1 and LAG-3 therapy may also develop cross-resistance to ipilimumab.